Eledon Pharmaceuticals, Inc

(NASDAQ:NVUS)

Latest On Eledon Pharmaceuticals, Inc (NVUS):

Date/Time Type Description Signal Details
2020-12-11 12:20 ESTAnalyst RatingThe Analyst Target Price has increased from $23.37 to $35.Buy
2020-11-26 21:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-19 04:57 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 15:57 ESTNewsNovus Therapeutics EPS misses by $3.76N/A
2020-11-17 15:57 ESTNewsNovus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-17 12:26 ESTEarnings EstimateAn EPS average of -$1.71 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-08 00:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 9,098 shares.Buy
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 15,000 shares.Buy
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly disposed of 27 shares.Sell
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 12,942 shares.Buy
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly disposed of 12,942 shares.Sell
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 15,000 shares.Buy
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 4,000 shares.Buy
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 31,000 shares.Buy
2020-11-06 18:53 ESTInsider TradeGlobal Management LP Logos has indirectly acquired of 5,000 shares.Buy
2020-11-04 12:28 ESTAnalyst RatingThe Analyst Target Price has decreased from $23.7 to $23.37.Neutral
2020-11-03 06:23 ESTNewsEnrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular diseaseN/A
2020-10-06 09:41 ESTAnalyst RatingThe Analyst Target Price has increased from $1.32 to $23.7.Buy
2020-10-06 05:31 ESTStock SplitA stock split has occured on Oct 5, 2020 with a split factor of 1:18.Neutral
2020-10-03 04:35 ESTNewsNovus Therapeutics announces 1-for-18 reverse stock splitN/A
2020-09-26 13:35 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:41 ESTFinancialsCompany financials have been released.Neutral
2020-09-15 21:57 ESTNewsNovus Therapeutics, Inc. (NVUS) CEO Dr. David-Alexandre Gros on Novus Therapeutics Acquisition of Anelixis Therapeutics (Transcript)N/A
2020-08-26 13:22 ESTFinancialsCompany financials have been released.Neutral
2020-08-25 09:32 ESTAnalyst RatingThe Analyst Target Price has increased from $1.23 to $1.32.Buy
2020-08-18 09:19 ESTAnalyst RatingThe Analyst Target Price has decreased from $1.28 to $1.23.Neutral
2020-08-17 05:19 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:39 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:52 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:17 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 17:56 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:32 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 17:19 ESTFinancialsCompany financials have been released.Neutral
2020-06-26 09:32 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 05:15 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 05:37 ESTFinancialsCompany financials have been released.Neutral
2020-06-09 09:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $2.12 to $1.28.Neutral
2020-06-03 09:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $2.75 to $2.12.Neutral
2020-06-02 09:17 ESTEarnings EstimateAn EPS average of -$0.11 is estimated for the quarter ending on September 30, 2020.Buy
2020-06-02 09:17 ESTAnalyst RatingThe Analyst Target Price has increased from $2.58 to $2.75.Buy
2020-06-01 20:04 ESTNewsNovus Therapeutics down big on failed ear infection studyN/A
2020-05-27 05:44 ESTFinancialsCompany financials have been released.Neutral
2020-05-20 21:20 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 10:50 ESTNewsNovus Therapeutics EPS misses by $0.31N/A
2020-05-06 05:49 ESTFinancialsCompany financials have been released.Neutral

About Eledon Pharmaceuticals, Inc (NVUS):

Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

NVUS Quotes by TradingView

See Advanced Chart

General

  • Name Eledon Pharmaceuticals, Inc
  • Symbol NVUS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 7
  • Last Split Factor1:18
  • Last Split Date2020-10-05
  • Fiscal Year EndDecember
  • IPO Date2014-09-17
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://novustherapeutics.com
View More

Valuation

  • Trailing PE 2.09
  • Price/Book (Most Recent Quarter) 1.03
  • Enterprise Value EBITDA 7.72
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$1.80
  • Return on Assets -7%
  • Return on Equity -21%
  • Earnings Per Share -$1.70
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 20.97 million
  • EBITDA -17030000
  • PEG Ratio 0.01
  • Analyst Target Price $35
  • Book Value Per Share $16.87
View More

Share Statistics

  • Shares Outstanding 1.44 million
  • Shares Float 1.29 million
  • % Held by Insiders 17%
  • % Held by Institutions 13.13%
  • Shares Short 108935
  • Shares Short Prior Month 117523
  • Short Ratio 4.96
  • Short % of Float 10%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 2.31
  • 52 Week High $26.44
  • 52 Week Low $4.5
  • 50 Day Moving Average 15.71
  • 200 Day Moving Average 15.63
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Eledon Pharmaceuticals, Inc (NVUS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eledon Pharmaceuticals, Inc (NVUS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-16$N/A-$5.51-$1.75-215.45%
2020-06-302020-08-14$N/A-$2.70-$2.979.09%
2020-03-312020-05-15$N/A-$8.46-$2.88-193.75%
2019-12-312020-03-17$N/A-$4.86-$4.68-3.85%
2019-09-302019-11-13$N/A-$3.96-$7.2945.68%
2019-06-302019-08-13$N/A-$6.30-$7.6517.65%
2019-03-312019-05-14$N/A-$9.36-$8.73-7.22%
2018-12-312019-03-28$N/A-$8.82-$7.20-22.5%
2018-09-302018-11-13$N/A-$6.66-$7.207.5%
2018-06-302018-08-07$N/A-$6.12-$5.58-9.68%
2018-03-312018-05-11$N/A-$6.48-$5.22-24.14%
2017-09-302017-11-08$N/A-$0.43
2017-06-302017-08-09$N/A-$1.32-$2.7051.11%
2017-03-312017-05-03$N/A-$1.53-$2.7043.33%
2016-12-312017-03-03$N/A-$1.53-$3.0650%
2016-09-302016-11-03$N/A-$3.69-$3.823.4%
2016-06-302016-08-04$N/A-$5.40-$4.82-12.03%
2016-03-312016-05-10$N/A-$4.59-$4.52-1.55%
2015-12-312016-03-10$N/A-$4.41-$4.25-3.76%
2015-09-302015-11-10$N/A-$4.77-$4.52-5.53%
2015-06-302015-08-12$N/A-$3.60-$5.1530.1%
2015-03-312015-05-12$N/A-$0.59-$0.31-90.32%
2014-12-312015-03-12-$0.28-$0.3417.65%
2014-09-302014-11-10$N/A-$2.71-$0.36-652.78%

Eledon Pharmaceuticals, Inc (NVUS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 1.65 million 1.33 million 1.51 million
Income Before Tax N/A N/A -8.18 million -4.14 million -2.89 million
Selling General Administrative N/A N/A 1.73 million 967000 1.41 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -3.33 million -2.3 million -2.92 million
Operating Income N/A N/A -3.38 million -2.3 million -2.92 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A -4.8 million -1.84 million 27000
Net Income From Continuing Operations N/A N/A -8.18 million -4.14 million -2.89 million
Net Income Applicable to Common Shares -6.14 million -2.59 million N/A -4.14 million -2.89 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 4.24 million -785000 N/A -342000 N/A
Total Cash Flow from Investing Activities 11.04 million N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 5.19 million N/A N/A
Change to Operating Activities 415000 107000 N/A 307000 N/A
Change in Cash N/A N/A 2.99 million -2.02 million N/A
Total Cash from Operating Activities -561000 -3.02 million -2.2 million -2.02 million N/A
Depreciation N/A N/A 46000 46000 N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 878000 197000 N/A 2.11 million N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 1.98 million 1.47 million 1.85 million
Total Stockholder Equity N/A N/A 11.75 million 9.47 million 13.37 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A 13.72 million 10.93 million 15.22 million
Common Stock 1000 19000 N/A 13000 13000
Other Current Assets N/A N/A 64000 N/A N/A
Retained Earnings -74.49 million -68.35 million -65.76 million -57.58 million -53.44 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 32.84 million 511000 N/A 639000 688000
Cash N/A N/A 11.79 million 8.79 million 10.81 million
Total Current Liabilities 6.13 million N/A 1.88 million 1.32 million 1.66 million
Other Stockholder Equity 164.95 million N/A N/A N/A N/A
Property, Plant & Equipment 183000 229000 N/A 321000 367000
Total Current Assets 115.1 million N/A 12.87 million 9.97 million 12.3 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 141.99 million 9.36 million N/A 9.47 million 11.5 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 758000 N/A 741000 329000 256000

Eledon Pharmaceuticals, Inc (NVUS) Chart:

Eledon Pharmaceuticals, Inc (NVUS) News:

Below you will find a list of latest news for Eledon Pharmaceuticals, Inc (NVUS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eledon Pharmaceuticals, Inc (NVUS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Eledon Pharmaceuticals, Inc (NVUS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020029654/0001564590-20-029654-index.htm
2018-07-31UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1404281/000000000018023476/0000000000-18-023476-index.htm
2019-06-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1404281/000000000019009796/0000000000-19-009796-index.htm
2020-03-31UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1404281/000000000020002791/0000000000-20-002791-index.htm
2018-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318007642/0000899243-18-007642-index.htm
2018-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318007647/0000899243-18-007647-index.htm
2018-03-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318007648/0000899243-18-007648-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318016652/0000899243-18-016652-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318016653/0000899243-18-016653-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318016654/0000899243-18-016654-index.htm
2018-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318016655/0000899243-18-016655-index.htm
2018-09-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318024043/0000899243-18-024043-index.htm
2018-09-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924318024470/0000899243-18-024470-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319008139/0000899243-19-008139-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319008140/0000899243-19-008140-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319008141/0000899243-19-008141-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319019597/0000899243-19-019597-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319019598/0000899243-19-019598-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319019599/0000899243-19-019599-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319019600/0000899243-19-019600-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319019601/0000899243-19-019601-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319024431/0000899243-19-024431-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319024432/0000899243-19-024432-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924319024433/0000899243-19-024433-index.htm
2020-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320009124/0000899243-20-009124-index.htm
2020-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320009125/0000899243-20-009125-index.htm
2020-03-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320009126/0000899243-20-009126-index.htm
2020-09-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320025163/0000899243-20-025163-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320025165/0000899243-20-025165-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320025166/0000899243-20-025166-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320025169/0000899243-20-025169-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320025170/0000899243-20-025170-index.htm
2020-09-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320025172/0000899243-20-025172-index.htm
2020-09-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320026299/0000899243-20-026299-index.htm
2020-09-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000089924320026300/0000899243-20-026300-index.htm
2018-03-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000091957418002420/0000919574-18-002420-index.htm
2018-03-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000091957418002573/0000919574-18-002573-index.htm
2019-05-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000091957419003096/0000919574-19-003096-index.htm
2019-06-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000091957419003970/0000919574-19-003970-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000091957420001268/0000919574-20-001268-index.htm
2019-05-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000092189519001354/0000921895-19-001354-index.htm
2020-10-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000092189520002527/0000921895-20-002527-index.htm
2020-10-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000092189520002529/0000921895-20-002529-index.htm
2018-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000094787118000249/0000947871-18-000249-index.htm
2019-05-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000094787119000328/0000947871-19-000328-index.htm
2019-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000094787119000336/0000947871-19-000336-index.htm
2019-05-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000094787119000337/0000947871-19-000337-index.htm
2020-02-25SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000094787120000143/0000947871-20-000143-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000094787120000145/0000947871-20-000145-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000094787120000146/0000947871-20-000146-index.htm
2020-08-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000094787120000691/0000947871-20-000691-index.htm
2020-10-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000094787120000795/0000947871-20-000795-index.htm
2019-07-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000101359419000483/0001013594-19-000483-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1404281/000101359420000123/0001013594-20-000123-index.htm
2018-01-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000107261318000016/0001072613-18-000016-index.htm
2018-05-02SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000107261318000306/0001072613-18-000306-index.htm
2018-05-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000107261318000344/0001072613-18-000344-index.htm
2019-04-05SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000110465919020047/0001104659-19-020047-index.htm
2018-04-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1404281/000119312518119824/0001193125-18-119824-index.htm
2018-07-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1404281/000119312518223696/0001193125-18-223696-index.htm
2018-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1404281/000119312518231910/0001193125-18-231910-index.htm
2018-08-01S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1404281/000119312518233511/0001193125-18-233511-index.htm
2018-09-04S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1404281/000119312518266270/0001193125-18-266270-index.htm
2018-09-07RWRegistration Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1404281/000119312518268697/0001193125-18-268697-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404281/000119312519129270/0001193125-19-129270-index.htm
2019-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1404281/000119312519130755/0001193125-19-130755-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312519135059/0001193125-19-135059-index.htm
2019-06-07S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1404281/000119312519168171/0001193125-19-168171-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1404281/000119312519173656/0001193125-19-173656-index.htm
2019-06-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1404281/000119312519185998/0001193125-19-185998-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312519193205/0001193125-19-193205-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312519218112/0001193125-19-218112-index.htm
2020-01-14424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1404281/000119312520007238/0001193125-20-007238-index.htm
2020-01-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312520008426/0001193125-20-008426-index.htm
2020-01-16424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1404281/000119312520009007/0001193125-20-009007-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312520041903/0001193125-20-041903-index.htm
2020-02-208-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312520042564/0001193125-20-042564-index.htm
2020-03-25S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1404281/000119312520085060/0001193125-20-085060-index.htm
2020-03-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1404281/000119312520085077/0001193125-20-085077-index.htm
2020-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312520240108/0001193125-20-240108-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312520246314/0001193125-20-246314-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000119312520264806/0001193125-20-264806-index.htm
2020-10-23PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1404281/000119312520275595/0001193125-20-275595-index.htm
2019-05-10DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000120919119028847/0001209191-19-028847-index.htm
2020-01-27DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000120919120004993/0001209191-20-004993-index.htm
2020-09-25DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000120919120052086/0001209191-20-052086-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000156218019003051/0001562180-19-003051-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000156218019003052/0001562180-19-003052-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000156218019003055/0001562180-19-003055-index.htm
2017-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459017022812/0001564590-17-022812-index.htm
2017-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459017024356/0001564590-17-024356-index.htm
2018-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459018005165/0001564590-18-005165-index.htm
2018-04-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404281/000156459018007314/0001564590-18-007314-index.htm
2018-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459018007316/0001564590-18-007316-index.htm
2018-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1404281/000156459018009747/0001564590-18-009747-index.htm
2018-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404281/000156459018009751/0001564590-18-009751-index.htm
2018-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459018013090/0001564590-18-013090-index.htm
2018-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459018013100/0001564590-18-013100-index.htm
2018-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459018015631/0001564590-18-015631-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459018019519/0001564590-18-019519-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459018019667/0001564590-18-019667-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459018028982/0001564590-18-028982-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459018029134/0001564590-18-029134-index.htm
2019-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459019000367/0001564590-19-000367-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404281/000156459019009631/0001564590-19-009631-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459019009676/0001564590-19-009676-index.htm
2019-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459019012158/0001564590-19-012158-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459019019134/0001564590-19-019134-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459019019162/0001564590-19-019162-index.htm
2019-05-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1404281/000156459019019430/0001564590-19-019430-index.htm
2019-05-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404281/000156459019019437/0001564590-19-019437-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459019031785/0001564590-19-031785-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459019031828/0001564590-19-031828-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459019043039/0001564590-19-043039-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459019043080/0001564590-19-043080-index.htm
2020-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020003758/0001564590-20-003758-index.htm
2020-03-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1404281/000156459020010887/0001564590-20-010887-index.htm
2020-03-1710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1404281/000156459020011260/0001564590-20-011260-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020011277/0001564590-20-011277-index.htm
2020-03-31DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1404281/000156459020014525/0001564590-20-014525-index.htm
2020-03-31DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1404281/000156459020014526/0001564590-20-014526-index.htm
2020-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1404281/000156459020014979/0001564590-20-014979-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020018029/0001564590-20-018029-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020025038/0001564590-20-025038-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459020025612/0001564590-20-025612-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020025631/0001564590-20-025631-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1404281/000156459020029654/0001564590-20-029654-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1404281/000156459020040128/0001564590-20-040128-index.htm
2020-09-15424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1404281/000156459020043577/0001564590-20-043577-index.htm
2020-11-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000156761920018885/0001567619-20-018885-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2018-07-31EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1404281/999999999518001961/9999999995-18-001961-index.htm
2019-06-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1404281/999999999519001363/9999999995-19-001363-index.htm
2020-04-03EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1404281/999999999520000680/9999999995-20-000680-index.htm

Eledon Pharmaceuticals, Inc (NVUS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eledon Pharmaceuticals, Inc (NVUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 17%
Institutional Ownership: 1313%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-04-30LIFESCI INDEX PARTNERS LLC10% Share HolderSell200.002.70540.001,065,867.00https://www.sec.gov/Archives/edgar/data/1404281/000091957419003096/0000919574-19-003096-index.htm
2018-03-13Jon KuwaharaOfficerBuy11,250.0011,250.00https://www.sec.gov/Archives/edgar/data/1404281/000089924318007648/0000899243-18-007648-index.htm
2018-03-13GREGORY J. FLESHERChief Executive OfficerBuy30,700.00146,556.00https://www.sec.gov/Archives/edgar/data/1404281/000089924318007647/0000899243-18-007647-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy5,000.0024.03120,162.50150,000.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2019-05-21GREGORY J. FLESHERChief Executive OfficerSell2,937.001.915,613.78156,918.00https://www.sec.gov/Archives/edgar/data/1404281/000156218019003051/0001562180-19-003051-index.htm
2019-05-20GREGORY J. FLESHERChief Executive OfficerSell11,701.001.9622,952.68159,855.00https://www.sec.gov/Archives/edgar/data/1404281/000156218019003051/0001562180-19-003051-index.htm
2019-03-14GREGORY J. FLESHERChief Executive OfficerBuy25,000.00171,556.00https://www.sec.gov/Archives/edgar/data/1404281/000089924319008140/0000899243-19-008140-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy31,000.0024.53760,426.90181,000.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy4,000.0025.97103,892.00185,000.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderSell12,942.0026.64344,829.24187,058.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderSell27.0027.02729.54199,973.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy12,942.0025.88334,926.02200,000.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy15,000.0026.48397,236.00200,000.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy15,000.0026.17392,610.00214,973.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2020-10-30Global Management LP Logos10% Share HolderBuy9,098.0025.55232,460.27224,071.00https://www.sec.gov/Archives/edgar/data/1404281/000156761920018886/0001567619-20-018886-index.htm
2019-05-02Erez ChimovitsDirectorBuy646,204.003.102,003,232.403,183,314.00https://www.sec.gov/Archives/edgar/data/1404281/000094787119000336/0000947871-19-000336-index.htm
2019-05-02Israel GP Ltd. OrbiMedDirectorBuy646,204.003.102,003,232.403,183,314.00https://www.sec.gov/Archives/edgar/data/1404281/000094787119000337/0000947871-19-000337-index.htm
2018-03-13CATHERINE C. TURKELPresidentBuy20,000.0044,519.00https://www.sec.gov/Archives/edgar/data/1404281/000089924318007642/0000899243-18-007642-index.htm
2019-05-21Jon KuwaharaOfficerSell1,058.001.912,022.265,974.00https://www.sec.gov/Archives/edgar/data/1404281/000156218019003052/0001562180-19-003052-index.htm
2018-09-11CATHERINE C. TURKELPresidentBuy17,048.004.5677,670.6961,567.00https://www.sec.gov/Archives/edgar/data/1404281/000089924318024470/0000899243-18-024470-index.htm
2019-05-20Jon KuwaharaOfficerSell4,218.001.968,274.037,032.00https://www.sec.gov/Archives/edgar/data/1404281/000156218019003052/0001562180-19-003052-index.htm
2018-09-12CATHERINE C. TURKELPresidentBuy16,632.005.0283,476.0178,199.00https://www.sec.gov/Archives/edgar/data/1404281/000089924318024470/0000899243-18-024470-index.htm
2018-09-05CATHERINE C. TURKELPresidentBuy805.003.973,192.63805.00https://www.sec.gov/Archives/edgar/data/1404281/000089924318024043/0000899243-18-024043-index.htm
2019-05-21CATHERINE C. TURKELPresidentSell1,914.001.913,658.4288,662.00https://www.sec.gov/Archives/edgar/data/1404281/000156218019003055/0001562180-19-003055-index.htm
2019-05-20CATHERINE C. TURKELPresidentSell7,623.001.9614,953.2890,576.00https://www.sec.gov/Archives/edgar/data/1404281/000156218019003055/0001562180-19-003055-index.htm
2019-03-14CATHERINE C. TURKELPresidentBuy20,000.0098,199.00https://www.sec.gov/Archives/edgar/data/1404281/000089924319008141/0000899243-19-008141-index.htm